CellSource Co., Ltd. (JP:4880) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
CellSource Co., Ltd. experienced a significant shortfall in its fiscal year results compared to earlier forecasts due to challenges in implementing synovium-derived stem cell services. The company reported a 69.3% drop in operating profit, leading to a downward revision in earnings expectations. Despite the setback, CellSource will continue its collaboration with medical institutions to develop these services.
For further insights into JP:4880 stock, check out TipRanks’ Stock Analysis page.